In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
News|Articles|May 20, 2026
What Patients Should Look Forward to at ASCO 2026
Author(s)Spencer Feldman
Fact checked by: CURE staff
ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.
Advertisement
Advertisement
Dr. Josh K. Sabari, a thoracic medical oncologist at NYU Langone’s Perlmutter Cancer Center and editor-in-chief of CURE, discussed the most anticipated lung cancer data expected at the 2026 ASCO Annual Meeting in an interview with CURE, highlighting biomarker-driven care, targeted therapies and expanding treatment modalities across solid tumors.
Related to this article
Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
The FDA withdrew Zepzelca’s accelerated approval for small cell lung cancer after the LAGOON trial failed to show longer survival. Its maintenance use with Tecentriq is unaffected.
In the phase 3 MAVERICK trial, people with small cell lung cancer who had regular brain MRIs instead of preventive whole-brain radiation kept their memory and thinking intact longer, with no clear survival difference so far.
The FDA has granted two Breakthrough Therapy Designations to AbbVie's investigational drug Temab-A, one for use in metastatic colorectal cancer and one for non-small cell lung cancer, based on early-phase trial data.
A Phase 3 trial of firmonertinib did not meet its main goal in a hard-to-treat lung cancer subtype, though the drug caused fewer serious side effects than chemotherapy.
Advertisement
Advertisement